Heterocyclic compounds and uses thereof

US10647716B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10647716-B2
Application numberUS-201916441610-A
CountryUS
Kind codeB2
Filing dateJun 14, 2019
Priority dateSep 21, 2015
Publication dateMay 12, 2020
Grant dateMay 12, 2020

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Provided herein are heterocyclic compounds of Formula (I), pharmaceutical compositions containing such a compound and their therapeutic uses, methods for their preparation, intermediate compounds, pharmaceutical compositions containing such a compound, and their therapeutic uses.

First claim

Opening claim text (preview).

What is claimed is: 1. A process of making compound 13: said process comprising contacting compound 12: with potassium tert-butoxide and iodomethane under conditions sufficient to form compound 13. 2. A process of making compound P-002: said process comprising contacting compound 13: with compound 13b: in the presence of [1,1′-Bis(diphenyl-phosphino)ferrocene]dichloropalladium(II) under conditions sufficient to form compound P-002. 3. A process of making a compound P-001: said process comprising contacting compound P-002: with lithium hydroxide under conditions sufficient to form compound P-001. 4. A compound of formula: 5. A method for treating acute myeloid leukemia comprising administering to a subject in need thereof an effective amount of a compound of formula: or a pharmaceutically acceptable salt thereof, and azacitidine. 6. A method for treating ovarian cancer comprising administering to a subject in need thereof an effective amount of a compound of formula: or a pharmaceutically acceptable salt thereof, and carboplatin.

Assignees

Inventors

Classifications

  • Drugs for disorders of the cardiovascular system · CPC title

  • of urine or of the urinary tract, e.g. urine acidifiers · CPC title

  • for myasthenia gravis · CPC title

  • Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis · CPC title

  • Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10647716B2 cover?
Provided herein are heterocyclic compounds of Formula (I), pharmaceutical compositions containing such a compound and their therapeutic uses, methods for their preparation, intermediate compounds, pharmaceutical compositions containing such a compound, and their therapeutic uses.
Who is the assignee on this patent?
Plexxikon Inc
What technology area does this patent fall under?
Primary CPC classification C07D471/04. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).